Express Pharma

Glenmark launches Teneligliptin + Pioglitazone Fixed-Dose Combination drug for type-II diabetes in India

The company has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) + Pioglitazone (15 mg), to be taken once a day

1 365

Glenmark Pharma has launched a novel Fixed-Dose Combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. This is the only available DPP4 and Glitazone combination brand in India for adults with uncontrolled type-II diabetes, Glenmark informed in a statement.

The company has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) + Pioglitazone (15 mg), to be taken once a day, the statement added.

It also notified that Glenmark is the first company in India to market the innovative FDC of Teneligliptin + Pioglitazone, which is approved by the Drug Controller General of India (DCGI).  This Fixed-Dose Combination will be useful